Novartis Begins CAR-T Payment Experiments With Outcomes-Based Contract With CMS
The Centers for Medicare and Medicaid Services will only pay for Kymriah if patients respond after one month. Novartis also pursuing similar contracts with private payers.
You may also be interested in...
ICER's review of available clinical trial data along with associated treatment and hospital costs found that Novartis' Kymriah and Gilead/Kite's Yescarta generally would not break the health care bank.
At recent industry events, Novartis and Kite Pharma highlighted opportunities and addressed challenges they face as they prepare to commercialize their CAR-T therapies. A report from Datamonitor Healthcare.
Novartis exec discusses details around its agreements with CMS for outcomes based payments and indication-based pricing for Kymriah.